CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study (Contract 22)

Related Notice: 75D301-22-R-72117

Contract Award Number: 75D30122C13322

Description: CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (MASS) Study
The primary purpose of the multistate assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) is to estimate the proportion of people that have been infected by or vaccinated for SARS-CoV-2 during the ongoing epidemic over time, nationally, and by geographic location and demographic/pediatric subcategory. For the eleven (11) jurisdictions awarded by the contract, the Contractor will identify excess, remnant, or residual blood specimens from remaining volumes of previously obtained blood specimens for non-COVID-19 diagnostic or antibody testing. More specifically - collect and test mass amounts of specimens for CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and/or IgM serological assays, as well as reflexive microneutralization testing for specimens that are seropositive by qualitative anti-nucleocapsid assay.

Performance Period: Base 11-month period, and one (1) 12-month option period